IP Library Granted Patent US 9,657,132
Granted Patent B2
US 9,657,132 · App. 14/438,565 · Granted May 23, 2017

Amine-functionalized polymeric compositions for medical devices

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,657,132
App. No.
14/438,565
Granted
May 23, 2017
Kind
B2
Abstract

The present disclosure provides amine-modified polymer foams, which may be used for wound dressing materials. For example, the modified materials can include a covalently attached molecule comprising free amine groups. Such amine groups can be used, for instance, to conjugate biologically active polypeptides and/or linkers. Methods for using modified polymers are also provided.

Claims (22)

1. A functionalized material comprising an amine-functionalized polyurethane material attached to a biologically active agent, wherein the amine-functionalized polyurethane material comprises a polyurethane polymer copolymerized with one or more aminoglycosides, and wherein the biologically active agent is attached to a free amino group on the functionalized material.

2. The functionalized material of claim 1 , wherein the one or more aminoglycosides comprise one or more aminoglycosides selected from the group consisting of amikacin, apramycin, arbekacin, astromicin, bekanamycin, dibekacin, framycetin, gentamicin, hygromycin B, isepamicin, kanamycin, neomycin, netilmicin, paromomycin, rhodostreptomycin, ribostamycin, sisiomycin, streptomycin, tobramycin, and verdamicin.

3. The functionalized material of claim 1 , wherein the biologically active agent is attached to the material through an adapter.

4. The functionalized material of claim 1 , wherein the biologically active agent is a polypeptide.

5. The functionalized material of claim 4 , wherein the polypeptide is selected from the group consisting of gelatin, collagen, albumin, an enzyme, growth factor, chemokine, cytokine, and a polypeptide that binds to any of them.

6. The functionalized material of claim 5 , wherein the polypeptide is an enzyme selected from a protease, hydrolase, lyase, ligase, isomerase, transferase, oxidase, reductase, oxidoreductase, synthase, polymerase, kinase, and phosphatase.

7. The functionalized material of claim 1 , comprising a polyurethane foam.

8. The functionalized material of claim 7 , comprising an open cell foam.

9. The functionalized material of claim 1 , wherein the amine-functionalized polyurethane material comprises a polyurethane polymer copolymerized with neomycin.

10. The functionalized material of claim 9 , in the form of a foam, solid membrane, semi-solid membrane, permeable membrane, semi-permeable membrane, interfacial layer, bead coating, catheter coating, stent coating, wound dressing, or coating for other device.

11. The functionalized material of claim 1 , wherein the biologically active agent is directly attached to the functionalized polyurethane material.

12. The functionalized material of claim 3 , wherein the adapter is an amine to amine crosslinker.

13. The functionalized material of claim 12 , wherein the amine-to-amine crosslinker is selected from malondialdehyde, succinaldehyde, phthalaldehyde, glutaraldehyde, and glyoxal.

14. The functionalized material of claim 12 , wherein the crosslinker is glutaraldehyde.

15. The functionalized material of claim 12 , wherein the adapter is cleavable.

16. The functionalized material of claim 10 , wherein the material comprises a foam that is a reticulated open-celled foam.

17. A method for treating a wound site, comprising:

applying a functionalized material according to claim 1 to a wound site; and

applying negative pressure to the wound site.

18. The method of claim 17 , further comprising applying an instillation solution to the wound site.

19. The method of claim 17 , wherein the biologically active agent comprises a polypeptide.

20. The method of claim 18 , wherein the instillation solution includes one or more agents that modulate a release of the biologically active agent.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2024
From: 3M INNOVATIVE PROPERTIES COMPANY
To: SOLVENTUM INTELLECTUAL PROPERTIES COMPANY
Reel/Frame 066430/0333 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 25, 2023
From: KCI LICENSING, INC.
To: 3M INNOVATIVE PROPERTIES COMPANY
Reel/Frame 064718/0544 →
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Nov 7, 2019
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: KCI USA, INC.; KCI LICENSING, INC.
Reel/Frame 050966/0547 →
RELEASE OF SECURITY INTEREST REEL/FRAME 040098/0268 Recorded Feb 8, 2017
From: WILMINGTON TRUST
To: KCI USA, INC.
Reel/Frame 041666/0320 →
LIMITED THIRD LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Oct 7, 2016
From: KCI USA, INC.; LIFECELL CORPORATION; KCI LICENSING, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 040291/0237 →
SECOND LIEN SECURITY AGREEMENT Recorded Sep 21, 2016
From: KCI USA, INC.; LIFECELL CORPORATION; KCI LICENSING, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 040098/0268 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 1, 2015
From: HANSON, DOUGLAS PHILIP; COURAGE, JAMES
To: KCI LICENSING, INC.
Reel/Frame 036465/0028 →